Laramo (Lacosamide)

Lacosamide is an anticonvulsant that acts on neuronal sodium channels to control seizure activity.

• Partial‑onset seizures (epilepsy): reduces seizure frequency as adjunctive therapy in focal epilepsy.
• Adjunctive therapy for refractory focal epilepsy: provides additional seizure control when other antiepileptics are insufficient.
• Epilepsy in adults and children (≥4 years): approved for use as part of a comprehensive seizure management plan.

• Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, stabilizing hyperexcitable neuronal membranes and limiting repetitive neuronal firing. By selectively targeting the slow inactivation pathway, it reduces the propagation of epileptiform activity without markedly affecting normal neuronal conduction.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Dizziness: transient sensation of light‑headedness or imbalance.
• Nausea: mild to moderate gastrointestinal upset.
• Headache: occasional tension‑type headache.
• Fatigue: feeling unusually tired or weak.
• Blurred vision: temporary visual disturbances.
• Diplopia: double vision, especially at higher doses.

Serious or Rare Side Effects

• Cardiac conduction abnormalities: PR‑interval prolongation or arrhythmias.
• Suicidal ideation: emergence of depressive thoughts or behaviors.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hypersensitivity: rash, angioedema, or anaphylaxis.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Respiratory depression: especially when combined with other CNS depressants.

When prescribing or dispensing lacosamide, consider the following safety measures.

• Renal impairment: assess kidney function and adjust dosing if necessary.
• Hepatic impairment: monitor liver enzymes and use caution in patients with liver disease.
• Cardiac conduction disorders: avoid in patients with known PR‑interval prolongation or arrhythmias.
• Pregnancy: safety not established; weigh potential benefits against risks.
• Concomitant CNS depressants: monitor for additive sedation or respiratory effects.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Lacosamide can interact with several drug classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma levels.
• Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce therapeutic concentrations.
• Class III antiarrhythmics (e.g., amiodarone): additive effects on cardiac conduction.

Moderate Interactions (Monitor Closely)

• Other antiepileptic drugs (e.g., valproate, phenobarbital): may require dose adjustments.
• Alcohol: potentiates central nervous system depression.
• Tricyclic antidepressants: increased risk of dizziness and cardiac effects.